2017 年第 2 期 第 15 卷

希罗达同步放疗治疗晚期食管癌对患者生活质量的影响

作者：

单位：

关键词：希罗达食管癌放疗生活质量肿瘤标志物

• 摘要：
• 【摘要】目的 探讨希罗达联合放疗对晚期食管癌的治疗效果及对患者生活质量的影响。方法 回顾性分析2012年8月-2015年8月在我院接受非手术治疗的晚期食管癌患者的临床资料，根据其治疗方法的不同分为单纯放疗组和希罗达联合放疗组。观察两组患者的治疗效果和不良反应发生率，治疗1个月后，比较两组患者肿瘤标志物水平、生活质量的差别。结果 希罗达联合放疗组治疗的有效率为80.9%，明显高于单纯放疗组（61.9%）（Χ2=4.675，P=0.031）；两组患者治疗前的CEA、CA199和CA125水平无明显差别（t=-0.054、-0.024、0.015，P=0.478、0.490、0.494），治疗1月后，希罗达联合放疗组明显低于单纯放疗组（t=14.402、8.087、19.746，P<0.001）；治疗1月后，希罗达联合放疗组的躯体化、焦虑、抑郁和敌对得分明显低于单纯放疗组（t=10.497、16.905、6.896、11.037，P<0.001），而两组患者的人际关系敏感、强迫症状、恐怖、偏执和精神病得分无明显差别；两组患者恶心、呕吐、肝肾功能受损和骨髓抑制发生率无明显差别（P>0.05）。结论 希罗达联合放疗对晚期食管癌有较好的治疗效果，可明显改善患者的生活质量，具有应用价值。
• Objective To investigate the therapeutic effect of capecitabine combined with radiotherapy for advanced esophageal carcinoma and the influence on the quality of life of patients. Methods A retrospective was used to analysis the clinical data of patients with advanced esophageal cancer treated in our hospital from August 2012 to August 2015 , according to the treatment of different points for simple radiotherapy group and xeloda combined with radiotherapy group. The treatment effect and adverse reaction rate of the two groups were observed, and the difference of tumor marker level and quality of life were compared between the two groups after 1 months. Results Capecitabine combined with radiotherapy in treatment group, the rate was 80.9%, significantly higher than radiotherapy alone group (61.9%) (x 2=4.675, P = 0.031); Two groups of patients before CEA, CA199, CA125 levels without significant difference (t=-0.054, 0.024, 0.015, P = 0.478, 0.490, 0.494), 1 month after treatment, xeloda combined with radiotherapy group was significantly lower than that of the radiotherapy group (t=14.402, 8.087, 19.746, P < 0.001). After 1 month of therapy. Capecitabine combined with radiotherapy group of somatization, anxiety, depression and hostility scores was significantly lower than that of the radiotherapy group (t=10.497, 16.905, greenhouse is 6.896, 11.037, P < 0.001), and two groups of patients with interpersonal sensitivity, compulsion symptoms, phobia, paranoid and psychotic score no significant difference; There was no significant difference between the two groups in the incidence of nausea, vomiting, liver and kidney function and bone marrow suppression (P>0.05). Conclusion Xeloda combined with radiotherapy for advanced esophageal cancer have a better therapeutic effect, can significantly improve the quality of life of patients, application value.